Black Diamond Therapeutics (BDTX) Price to Sales (2025)
Black Diamond Therapeutics' (BDTX) quarterly Price to Sales came in at 1.25 in Q1 2025.
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) Price to Sales (2025) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported Price to Sales for 1 consecutive years, with 1.25 the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Price to Sales changed N/A year-over-year to 1.25; the trailing twelve-month figure through Dec 2025 stood at 1.98 (changed N/A YoY), and the FY2025 full-year result was 1.98, changed N/A from the prior year.
- Price to Sales steadied at 1.25 in Q1 2025 per BDTX's latest filing.
- Across five years, Price to Sales topped out at 1.25 in Q1 2025 and bottomed at 1.25 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - |